Iambic Therapeutics: director Mary Tagliaferri received 20,300 shares

What happened Mary Tagliaferri, a director of Iambic Therapeutics, received a derivative award (an option) for 20,300 shares on Oct 14, 2026. The filing reports an acquisition price of $0.00 per share, for a total reported value of $0.

Key details

• transaction date: Oct 14, 2026; price: $0.00 per share; total: $0.
• transaction code: A (award/grant).
• security: derivative (option).
• vesting: all shares subject to the option vest on Oct 14, 2027 (footnote).
• shares owned after the transaction: not stated in the filing text provided.
• filing date: Oct 16, 2026 (accession 0001323304-26-000010).

Why it may matter

• this was an option grant, not a market sale.
• the filing shows a derivative award that vests on Oct 14, 2027.
• the filing does not show why the insider traded or why the company acted.